---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-048164"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:13:39.899078+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Humacyte regains ex-U.S. rights to Symvess from Fresenius, pays low-single-digit royalties

## Summary
- Humacyte obtains sole worldwide rights to develop and commercialize Symvess; Fresenius retains U.S. distribution terms unchanged.
- Humacyte will pay low-single-digit royalties on ex-U.S. net sales, with a two-year royalty-free period after launch in each country.
- Existing U.S. royalties to Fresenius remain at mid-single to low double digits; Fresenius must adopt Symvess as standard of care in hemodialysis if supported.
- Positions Humacyte to advance discussions with corporate partners for international and indication-specific rights.
- Humacyte CEO highlights planned international expansion in Saudi Arabia and Israel for vascular injury repair.

## SEC filing metadata
- accession: 0001104659-26-048164
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926048164/0001104659-26-048164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926048164/tm2612631d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-048164
- JSON: https://secwatch.observer/filing/0001104659-26-048164.json
- Plain text: https://secwatch.observer/filing/0001104659-26-048164.txt

## Source-grounded claims
- claim_id: 162b8f17fd25bd36b7b75900a78a6d49dcbaa777
  claim: Humacyte, Inc. amended Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc. valued at low-single-digit royalties on net sales (effective 2026-04-21).
  evidence_excerpt: On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926048164/0001104659-26-048164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.